

[View this email in your browser](#)



RACC-trial Newsletter January 2021

We are approaching the first interim analysis quicker than expected!

- As of January 28th, a total of 278 women have successfully been randomized in the trial (36%)
- The first interim analysis is planned at 300 patients
- At the current accrual rate, we should reach 300 early March 2022
- **For the interim analysis, all centers must enter baseline and follow-up data in the eCRF (PheedIT)**
- Please remember that according to the Clinical Trials Agreements, data input should be completed in the system within 30 days
- It is critical that the PI assists the local data manager to ensure correct input
- Please let us know if you need any further assistance related to data management and/or PheedIT

Deadline for data entering is March 31st 2022

Contact details

Sponsor

Henrik Falconer

henrik.falconer@sll.se

Co-PI

Sahar Salehi

sahar.salehi@sll.se

Chair translational research

Kolbrun Palsdottir

kolbrun.palsdottir@sll.se

Project manager

Katja Wiklund

Subscribe

Past Issues

Translate ▼

[Claudia Maes](#)
Claudia.maes@sll.se

Central monitor
[Anita Björk](#)
anita.bjork@sll.se



This email was sent to claudia.maes@sll.se
[why did I get this?](#) [unsubscribe from this list](#) [update subscription preferences](#)
Karolinska University Hospital · Karolinska Universitetssjukhuset · Stockholm 171 76 · Sweden

